- Home
- BMO vs VRTX Comparison
BMO vs VRTX Comparison
Compare BMO & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMO | VRTX |
|---|---|---|
| Founded | 1817 | 1989 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.2B | 128.8B |
| IPO Year | 2014 | 2006 |
Fundamental Metrics
Financial Performance| Metric | BMO | VRTX |
|---|---|---|
| Price | $165.71 | $501.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 32 |
| Target Price | $165.33 | ★ $571.39 |
| AVG Volume (30 Days) | 415.6K | ★ 834.6K |
| Earning Date | 08-25-2026 | 11-02-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | N/A | ★ 8.33 |
| Revenue | N/A | ★ $2,488,652,000.00 |
| Revenue This Year | $8.26 | $10.39 |
| Revenue Next Year | $4.76 | $9.83 |
| P/E Ratio | ★ $17.46 | $60.43 |
| Revenue Growth | N/A | ★ 46.20 |
| 52 Week Low | $119.84 | $402.58 |
| 52 Week High | $187.22 | $560.25 |
Technical Indicators
Market Signals| Indicator | BMO | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.50 | 38.21 |
| Support Level | $147.71 | $501.01 |
| Resistance Level | $177.35 | $506.93 |
| Average True Range (ATR) | 2.65 | 11.55 |
| MACD | -0.76 | -2.37 |
| Stochastic Oscillator | 20.64 | 17.07 |
Price Performance
Historical ComparisonAbout BMO Bank Of Montreal
Bank of Montreal is a diversified financial services provider based in North America with over CAD 1.47 trillion in assets by the end of fiscal 2025. BMO operates four business segments: Canadian personal and commercial banking, US personal and commercial banking, wealth management, and capital markets. About 60% of BMO's earnings are generated in Canada and 40% in the US.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.